Previous 10 | Next 10 |
home / stock / sdmhf / sdmhf news
Sartorius Stedim Biotech press release ( OTCPK:SDMHF ): 9M GAAP EPS of €6.58. Revenue of €2.6B (+23.2% Y/Y). Sales revenue up 17.0% in constant currencies, underlying EBITDA margin at 35.0%. Outlook for 2022 specified : Sales revenue growth ...
Nine-month results 2022 of Sartorius Stedim Biotech PR Newswire Sales revenue up 17.0 percent in constant currencies, underlying EBITDA margin at 35.0 percent Overall market situation characterized by innovations and strong growth drivers; current development as ex...
Summary I'm focused on high-quality companies with growing free cash flows per share. I group my portfolio into 4 buckets: Great capital allocations, Tech Leaders, (unprofitable) High-growth and short-term trades. I want to own companies with great management so that I can sle...
Sartorius Stedim Biotech to acquire Albumedix, strengthening its portfolio of innovative advanced therapy solutions PR Newswire UK-based Albumedix Ltd. is a leader in the field of recombinant albumin-based solutions and a highly innovative and profitable company Re...
Sartorius Stedim Biotech S.A. press release ( OTCPK:SDMHF ): 1H GAAP EPS of €4.40. Revenue of €1.72B (+27.4% Y/Y). 2022 outlook confirmed: Sales revenue expected to rise by 15 to 19 percent vs. estimated growth of 9.92% Y/Y and underlying ...
Half-year results 2022 of Sartorius Stedim Biotech PR Newswire AUBAGNE, France , July 21, 2022 Sales revenue up 22.1 percent in constant currencies, underlying EBITDA margin 35.2 percent 2022 outlook confirmed: Sales revenue expected...
Sartorius AG and Sartorius Stedim are a buy after a significant drawdown. Sartorius is operating in the fast-growing biopharmaceutical industry. The company is growing rapidly and with already high profitability. Sartorius French subsidiary is the more attractive stock between...
First-quarter results 2022 of Sartorius Stedim Biotech PR Newswire Sales revenue up 27.6 percent in constant currencies, underlying EBITDA margin 35.2 percent Healthy demand situation; normalization of pandemic-related effects and development of order int...
Sartorius records dynamic start to the new fiscal year PR Newswire Figures for the first quarter of 2022: Sales revenue up 25.4 percent in constant currencies, underlying EBITDA up 32.4 percent, underlying EBITDA margin 34.1 percent Healthy demand situation; normal...
Sartorius Stedim Biotech presents annual report for 2021 PR Newswire AUBAGNE, France , Feb. 17, 2022 /PRNewswire/ -- Sartorius Stedim Biotech, a leading partner of the biopharma industry, today has presented its Universal Registration Document 2021 including th...
News, Short Squeeze, Breakout and More Instantly...
Sartorius Stedim Biotech Company Name:
SDMHF Stock Symbol:
OTCMKTS Market:
Nine-month results 2022 of Sartorius Stedim Biotech PR Newswire Sales revenue up 17.0 percent in constant currencies, underlying EBITDA margin at 35.0 percent Overall market situation characterized by innovations and strong growth drivers; current development as ex...
Sartorius Stedim Biotech to acquire Albumedix, strengthening its portfolio of innovative advanced therapy solutions PR Newswire UK-based Albumedix Ltd. is a leader in the field of recombinant albumin-based solutions and a highly innovative and profitable company Re...
Half-year results 2022 of Sartorius Stedim Biotech PR Newswire AUBAGNE, France , July 21, 2022 Sales revenue up 22.1 percent in constant currencies, underlying EBITDA margin 35.2 percent 2022 outlook confirmed: Sales revenue expected...